Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Danish CEMTV (Centre for Evaluation and Health Technology Assessment) rejects screening for type 2 diabetes

This article was originally published in Clinica

Executive Summary

The introduction of population-based screening for type 2 diabetes cannot be recommended, says a recently published report from the Danish Centre for Evaluation and Health Technology Assessment (CEMTV). Claiming that there is no documented evidence that population-based screening improves prognosis - by reducing the risk of diabetic complications - the report says that there should instead be increased focus on clinical case detection in general practice.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel